PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
XBIT vs. XBI
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between XBIT and XBI is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

XBIT vs. XBI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in XBiotech Inc. (XBIT) and SPDR S&P Biotech ETF (XBI). The values are adjusted to include any dividend payments, if applicable.

-40.00%-20.00%0.00%20.00%AugustSeptemberOctoberNovemberDecember2025
-43.45%
-14.90%
XBIT
XBI

Key characteristics

Sharpe Ratio

XBIT:

-0.19

XBI:

-0.16

Sortino Ratio

XBIT:

0.34

XBI:

-0.05

Omega Ratio

XBIT:

1.04

XBI:

0.99

Calmar Ratio

XBIT:

-0.19

XBI:

-0.08

Martin Ratio

XBIT:

-0.55

XBI:

-0.47

Ulcer Index

XBIT:

29.18%

XBI:

8.60%

Daily Std Dev

XBIT:

85.72%

XBI:

25.25%

Max Drawdown

XBIT:

-92.67%

XBI:

-63.89%

Current Drawdown

XBIT:

-86.33%

XBI:

-50.10%

Returns By Period

In the year-to-date period, XBIT achieves a -6.08% return, which is significantly lower than XBI's -3.78% return.


XBIT

YTD

-6.08%

1M

-46.62%

6M

-43.45%

1Y

-25.80%

5Y*

-29.70%

10Y*

N/A

XBI

YTD

-3.78%

1M

-7.21%

6M

-14.90%

1Y

-4.02%

5Y*

-2.18%

10Y*

2.95%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

XBIT vs. XBI — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XBIT
The Risk-Adjusted Performance Rank of XBIT is 4040
Overall Rank
The Sharpe Ratio Rank of XBIT is 3939
Sharpe Ratio Rank
The Sortino Ratio Rank of XBIT is 4444
Sortino Ratio Rank
The Omega Ratio Rank of XBIT is 4444
Omega Ratio Rank
The Calmar Ratio Rank of XBIT is 3737
Calmar Ratio Rank
The Martin Ratio Rank of XBIT is 3838
Martin Ratio Rank

XBI
The Risk-Adjusted Performance Rank of XBI is 88
Overall Rank
The Sharpe Ratio Rank of XBI is 88
Sharpe Ratio Rank
The Sortino Ratio Rank of XBI is 99
Sortino Ratio Rank
The Omega Ratio Rank of XBI is 99
Omega Ratio Rank
The Calmar Ratio Rank of XBI is 88
Calmar Ratio Rank
The Martin Ratio Rank of XBI is 88
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

XBIT vs. XBI - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for XBiotech Inc. (XBIT) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for XBIT, currently valued at -0.19, compared to the broader market-2.000.002.00-0.19-0.16
The chart of Sortino ratio for XBIT, currently valued at 0.34, compared to the broader market-4.00-2.000.002.004.000.34-0.05
The chart of Omega ratio for XBIT, currently valued at 1.04, compared to the broader market0.501.001.502.001.040.99
The chart of Calmar ratio for XBIT, currently valued at -0.19, compared to the broader market0.002.004.006.00-0.19-0.08
The chart of Martin ratio for XBIT, currently valued at -0.55, compared to the broader market0.0010.0020.00-0.55-0.47
XBIT
XBI

The current XBIT Sharpe Ratio is -0.19, which is comparable to the XBI Sharpe Ratio of -0.16. The chart below compares the historical Sharpe Ratios of XBIT and XBI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.000.501.001.502.00AugustSeptemberOctoberNovemberDecember2025
-0.19
-0.16
XBIT
XBI

Dividends

XBIT vs. XBI - Dividend Comparison

XBIT has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.15%.


TTM20242023202220212020201920182017201620152014
XBIT
XBiotech Inc.
0.00%0.00%0.00%0.00%22.46%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
XBI
SPDR S&P Biotech ETF
0.15%0.15%0.02%0.00%0.04%0.20%0.00%0.28%0.24%0.26%0.61%1.07%

Drawdowns

XBIT vs. XBI - Drawdown Comparison

The maximum XBIT drawdown since its inception was -92.67%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for XBIT and XBI. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%-40.00%AugustSeptemberOctoberNovemberDecember2025
-86.33%
-50.10%
XBIT
XBI

Volatility

XBIT vs. XBI - Volatility Comparison

XBiotech Inc. (XBIT) has a higher volatility of 40.25% compared to SPDR S&P Biotech ETF (XBI) at 8.03%. This indicates that XBIT's price experiences larger fluctuations and is considered to be riskier than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%AugustSeptemberOctoberNovemberDecember2025
40.25%
8.03%
XBIT
XBI
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab